Opportunities

Research Opportunities

• A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis: Study of ABBV-142 to assess adverse events and change in disease activity in adult participants with Idiopathic Pulmonary Fibrosis.
• A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD) characterized by an eosinophilic phenotype (THESEUS)
• A multicenter, parallel-group, phase 2b, randomized, double-blind, placebo-controlled, 3-arm, 24-week study to evaluate the efficacy and safety of AZD6793 tablets in adult participants with moderate to very severe Chronic Obstructive Pulmonary Disease (PRESTO)
• A multinational, long-term, open-label extension study of subjects who have participated in Avalyn Pharma studies of inhaled antifibrotic agents (SAIL)
• MOMENTOUS study (iMpact Of an ecg ai ModEl oN The diagnosis Of pUlmonary hypertenSion): Multi-site study of the clinical impact of an AI-asisted approach to referring patients with Interstitial Lung Disease for diagnostic evaluation of Pulmonary Hypertension (MOMENTOUS)
• A randomized, double-blind, placebo-controlled, parallel group, multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab in adult participants with moderate to very severe Chronic Obstructive Pulmonary Disease (JOURNEY)
• Auxora for the treatment of AKI and modulation of injurious "crosstalk" with the lung: A randomized control trial (KOURAGE)
• A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adjunctive recombinant human plasma gelsolin with standard of care for moderate-to-severe ARDS due to pneumonia or other infections
• A test-negative case-control study to evaluate the effectiveness of V116, CAPVAXIVE against pneumococcal pneumonia in older adults
• Alpha-1 Foundation Therapeutic Development Network (Alpha-1 Research Registry) (TDN-001)
• A randomized, double-blind, palcebo-controlled study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (OCEAN-1)
• A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and tolerability of nebulized CSL787 in adults (18 to 85 years) with Non-Cystic Fibrosis Bronchiectasis
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week double-blind, placebo-controlled extension phase in participants with Idiopathic Pulmonary Fibrosis (ZAPPHIRE

Simulation Training

• Residents will participate in simulation-based education using the Apollo simulation platform, providing hands-on training in clinical decision-making, procedural skills, teamwork, and patient safety.
• Point-of-Care Ultrasound (POCUS) training will be incorporated into patient care through didactics, simulation, and direct clinical application.

Community Engagement Opportunities

• Local School Healthcare Club/Event Opportunities
• Volunteering at public events in Medical tents
  • Ex: Hannibal Cannibal (National Tom Sawyer Days Festival) and Mud Volleyball (National Tom Sawyer Days Festival)
• Hannibal Free Clinic
• Clarity Healthcare
• Douglass Community Center